The comprehensive ovarian cancer genomic studies revealed that hypermethylated-BRCA1 ovarian cancer with platinum therapy had a similar prognosis as the intact BRCA cancer, whereas BRCA1/BRCA2-mutated ovarian cancer showed better prognosis than the wild-type cancer (46, 47). This evidence concerns the gene BRCA1 and ovarian carcinoma.